Provided by Tiger Trade Technology Pte. Ltd.

HENGRUI PHARMA

43.560
-0.400-0.91%
Volume:1.38M
Turnover:59.89M
Market Cap:289.11B
PE:31.59
High:43.900
Open:43.900
Low:43.200
Close:43.960
52wk High:94.869
52wk Low:43.200
Shares:6.64B
HK Float Shares:258.00M
Volume Ratio:1.03
T/O Rate:0.53%
Dividend:0.23
Dividend Rate:0.54%
EPS(LYR):1.379
ROE:12.46%
ROA:7.02%
PB:3.84
PE(LYR):31.59
PS:7.90

Loading ...

Movement Alert|Hengrui Medicine Rises 3.73% in Regular Trading, First Self-Developed Innovative Drug Marketing Application Accepted by EMA

Market Focus
·
Jun 23

Hengrui Pharma's Novel Drug Application for Rezvilutamide Accepted by European Regulator

Stock News
·
Jun 22

AH Premium and Deviation Data for June 22

Stock News
·
Jun 22

Movement Alert|Hengrui Medicine Falls 3.02% in Regular Trading, Broad Pharma Sector Sell-Off Amid Geopolitical Headwinds

Market Focus
·
Jun 22

AH Share Premium and Deviation Rankings as of June 18th

Stock News
·
Jun 18

Movement Alert|Hengrui Medicine Rises 3.02% in Regular Trading, Multiple Drug Approvals and Institutional Buying Boost Sentiment

Market Focus
·
Jun 18

Schroders Increases Stake in Hengrui Pharma by 948,800 Shares at HK$54.54 Per Share

Stock News
·
Jun 17

Hengrui Pharma repurchases 120,000 A shares for ESOP; treasury stock rises to 8.31 million

Bulletin Express
·
Jun 17

Hengrui Pharma Executes Share Buyback on June 17

Stock News
·
Jun 17

China Greenlights Clinical Trials for Two Hengrui Pharma Drugs, Approves Another Indication for Breast Cancer Drug

MT Newswires Live
·
Jun 17

Jiangsu Hengrui Pharmaceuticals - Received Notice From Nmpa New Indication for Dalpiciclib Isethionate Tablets, Cdk4/6 Inhibitor Approved

THOMSON REUTERS
·
Jun 16

HENGRUI PHARMA Receives Clinical Trial Approval for SHR-6914 Injection

Stock News
·
Jun 16

AH Share Premium and Deviation Rankings for June 16 Closing

Stock News
·
Jun 16

Closing Data for June 15th: AH Premium and Deviation Rankings

Stock News
·
Jun 15

Innovative Drug Stocks See Broad Gains as Sector's Outbound Licensing Activity Remains Robust, Supported by Policy Tailwinds and Commercialization Progress

Stock News
·
Jun 12

Movement Alert|Hengrui Medicine Rises 3.43% in Regular Trading, Pipeline Momentum Sustained by EULAR Data and Ongoing Buybacks

Market Focus
·
Jun 12

Hengrui's Dual-Target Fusion Protein SHR-2173 Shows Promising Phase I Results for Lupus at EULAR 2026

Deep News
·
Jun 11

Hengrui Pharma repurchases 150,000 A-shares for ESOP at RMB 46.89 average

Bulletin Express
·
Jun 11

AH Share Premium and Deviation Rankings for June 11th

Stock News
·
Jun 11

Movement Alert|Hengrui Medicine Falls 3.06% in Regular Trading, Valuation Compression and Institutional Selling Continue to Weigh

Market Focus
·
Jun 11